How should procurement teams evaluate CDMO partners in the Cell Therapy Market?

Prioritise demonstrated batch success rate and release-testing turnaround over headline suite capacity. Ask for out-of-specification rates by product class, not aggregate figures. Contract terms should allocate risk for failed manufacture explicitly [9]. Read More

What vein-to-vein time should hospitals plan for in 2026?

Commercial autologous products typically run three to five weeks from apheresis to infusion, with bridging therapy required in most cases. Allogeneic products, once approved, would collapse this to days [17]. Read More

Do autoimmune indications change the Cell Therapy Market investment case?

Substantially. Lower tumour burden means milder toxicity and outpatient feasibility, which restructures the cost base entirely. The addressable population also exceeds relapsed haematologic malignancy by orders of magnitude [21]. Read More

How do outcomes-based agreements shift financial risk?

Manufacturers accept rebates when contracted clinical benefit is not achieved, transferring durability risk away from payers. States retain administrative burden and data-collection obligations [13]. Read More

Which delivery technology should Cell Therapy Market buyers watch — viral or non-viral?

Lentiviral vectors dominate approved products but carry fifteen-year follow-up obligations tied to insertional risk. Non-viral transposon and mRNA methods avoid that requirement and cost less, though clinical validation remains thinner [20]. Read More

What integration challenges face community oncology sites post-REMS?

Referral pathway design and co-management protocols with certified centres matter more than equipment. Staff triage training for cytokine release syndrome recognition is the practical gating factor [1]. Read More

Why does apheresis slot scarcity constrain trial enrolment?

Collection capacity is shared between commercial and investigational products, and commercial patients take priority. Sponsors increasingly contract dedicated slots in advance rather than compete for hospital availability [17]. Note: This is a sensitive clinical area. Nothing here constitutes medical advice; treatment decisions should be made with a qualified clinician. © 2026 Market Research Future marketresearchfuture.com Report ID: MRFR/HC/5066-CR Read More

Cell Therapy Market (2026 - 2035)

Cell Therapy Market Research Report: Size, Share, Trend Analysis By Applications (Oncology, Cardiovascular Disease, Neurological Disorders, Orthopedic Disorders), By Types (Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy), By Delivery Method (Intravenous Injection, Subcutaneous Injection, Intradermal Injection, Intramuscular Injection), By End Users (Hospitals, Research Institutions, Ambulatory Surgical Centers) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2026-2035

CAGR

16.1%

2025 Market Size

USD 5.97 Billion

2035 Market Size

USD 26.87 Billion

Life Sciences ● Updated August 2026 Report ID: MRFR/LS/3630-CR | Pages: 95 | Author: Vikita Thakur, Kinjoll Dey

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Report Takeaways |
1. 2.1 By Therapy Type |
2. 2.2 By Sector |
3. 2.3 By Geography
3 Global Market Size & Forecast (2021–2035) |
1. 3.1 Historical Market Size (2021–2025) |
2. 3.2 Current & Forecast Market Size (2026–2035) |
3. 3.3 Market Size by Revenue (USD Billion) |
4. 3.4 Year-over-Year Growth Analysis
4 Market Drivers Analysis |
1. 4.1 Deregulation of Delivery Sites |
2. 4.2 Outcomes-Based Payment Architecture |
3. 4.3 Earlier-Line Indication Creep |
4. 4.4 Manufacturing Throughput Economics
5 Market Restraints Analysis |
1. 5.1 Price and the Budget-Impact Ceiling |
2. 5.2 Tightening Evidentiary Standards |
3. 5.3 Delivery Infrastructure Lag
6 Market Opportunity Analysis |
1. 6.1 Autoimmune Indications as the Second Franchise |
2. 6.2 Off-the-Shelf Allogeneic Platforms |
3. 6.3 Emerging-Market Localisation |
4. 6.4 Registry-Linked Data Monetisation |
5. 6.5 Decentralised and Point-of-Care Manufacturing |
6. 6.6 Industry Value Chain Analysis |
7. 6.7 Porter's Five Forces Analysis
7 Regional Analysis |
1. 7.1 North America | |
  1. 7.1.1 US | |
  2. 7.1.2 Canada | |
  3. 7.1.3 Mexico |
2. 7.2 Europe | |
  1. 7.2.1 Germany | |
  2. 7.2.2 UK | |
  3. 7.2.3 France | |
  4. 7.2.4 Italy | |
  5. 7.2.5 Spain | |
  6. 7.2.6 Nordic Countries | |
  7. 7.2.7 Russia | |
  8. 7.2.8 Rest of Europe |
3. 7.3 Asia-Pacific | |
  1. 7.3.1 China | |
  2. 7.3.2 India | |
  3. 7.3.3 Japan | |
  4. 7.3.4 South Korea | |
  5. 7.3.5 ASEAN | |
  6. 7.3.6 Rest of Asia-Pacific |
4. 7.4 South America | |
  1. 7.4.1 Brazil | |
  2. 7.4.2 Argentina | |
  3. 7.4.3 Rest of South America |
5. 7.5 Middle East & Africa | |
  1. 7.5.1 Saudi Arabia | |
  2. 7.5.2 UAE | |
  3. 7.5.3 South Africa | |
  4. 7.5.4 Egypt | |
  5. 7.5.5 Rest of Middle East & Africa
8 Future Outlook (2026–2035) |
1. 8.1 Automation Replaces Artisanal Manufacturing |
2. 8.2 Outpatient Delivery Becomes Standard |
3. 8.3 Evidence Standards Reset the Competitive Bar |
4. 8.4 Payment Innovation Goes Multinational
9 Segmentation Analysis |
1. 9.1 By Therapy Type | |
  1. 9.1.1 Autologous Cell Therapy | |
  2. 9.1.2 Allogeneic Cell Therapy |
2. 9.2 By Cell Type | |
  1. 9.2.1 Immune Cell Therapy | |
  2. 9.2.2 Stem Cell Therapy | |
  3. 9.2.3 Other Cell Types |
3. 9.3 By Application | |
  1. 9.3.1 Oncology | |
  2. 9.3.2 Cardiovascular | |
  3. 9.3.3 Neurological Disorders | |
  4. 9.3.4 Musculoskeletal | |
  5. 9.3.5 Dermatology & Wound Care | |
  6. 9.3.6 Other Applications |
4. 9.4 By End User | |
  1. 9.4.1 Hospitals & Clinics | |
  2. 9.4.2 Specialized Cell- & Gene-Therapy Centres | |
  3. 9.4.3 Academic & Research Institutes | |
  4. 9.4.4 Others
10 Competitive Landscape |
1. 10.1 Market Share Analysis (2026) |
2. 10.2 Competitive Benchmarking Matrix |
3. 10.3 Company Profiles | |
  1. 10.3.1 Gilead Sciences (Kite Pharma) | |
  2. 10.3.2 Novartis | |
  3. 10.3.3 Bristol Myers Squibb | |
  4. 10.3.4 Johnson & Johnson (Janssen) | |
  5. 10.3.5 Legend Biotech | |
  6. 10.3.6 Vertex Pharmaceuticals | |
  7. 10.3.7 Iovance Biotherapeutics | |
  8. 10.3.8 Lonza | |
  9. 10.3.9 Mesoblast | |
  10. 10.3.10 Adaptimmune Therapeutics | |
  11. 10.3.11 Allogene Therapeutics | |
  12. 10.3.12 JW Therapeutics
11 Recent Developments & News
12 Report Scope & Methodology |
1. 12.1 Study Period & Base Year |
2. 12.2 Data Sources & Citations |
3. 12.3 Abbreviations
13 Detailed Sources and Citations
14 Frequently Asked Questions (FAQs)
15 LIST OF TABLES |
TABLE 1 Global Cell Therapy Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global Cell Therapy Market – Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Global Cell Therapy Market – Driver Impact Analysis, 2026–2035 |
TABLE 4 Global Cell Therapy Market – Restraint Impact Analysis, 2026–2035 |
TABLE 5 Global Cell Therapy Market Size, by Therapy Type, 2021–2035 (USD Billion) |
TABLE 6 Global Cell Therapy Market Size, by Cell Type, 2021–2035 (USD Billion) |
TABLE 7 Global Cell Therapy Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 8 Global Cell Therapy Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 9 Global Cell Therapy Market Size, by Region, 2021–2035 (USD Billion) |
TABLE 10 North America Cell Therapy Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 11 Europe Cell Therapy Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 12 Asia-Pacific Cell Therapy Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 13 South America Cell Therapy Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 14 Middle East & Africa Cell Therapy Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 15 North America Cell Therapy Market Size, by Therapy Type, 2021–2035 (USD Billion) |
TABLE 16 North America Cell Therapy Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 17 North America Cell Therapy Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 18 Europe Cell Therapy Market Size, by Therapy Type, 2021–2035 (USD Billion) |
TABLE 19 Europe Cell Therapy Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 20 Europe Cell Therapy Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 21 Asia-Pacific Cell Therapy Market Size, by Therapy Type, 2021–2035 (USD Billion) |
TABLE 22 Asia-Pacific Cell Therapy Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 23 Asia-Pacific Cell Therapy Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 24 South America Cell Therapy Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 25 Middle East & Africa Cell Therapy Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 26 US Cell Therapy Market Size, by Therapy Type, 2021–2035 (USD Billion) |
TABLE 27 China Cell Therapy Market Size, by Therapy Type, 2021–2035 (USD Billion) |
TABLE 28 Japan Cell Therapy Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 29 Germany Cell Therapy Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 30 Competitive Benchmarking Matrix – Global Cell Therapy Market, 2026 |
TABLE 31 Company Profiles – Key Players, Global Cell Therapy Market |
TABLE 32 Recent Developments & Strategic Announcements, 2023–2026 |
TABLE 33 Report Scope & Methodology Summary |
TABLE 34 Detailed Sources and Citations
16 LIST OF FIGURES |
FIGURE 1 Global Cell Therapy Market – Market Dynamics Overview (Drivers, Restraints, Opportunities) |
FIGURE 2 Global Cell Therapy Market – Industry Value Chain Analysis |
FIGURE 3 Global Cell Therapy Market – Porter's Five Forces Analysis |
FIGURE 4 Global Cell Therapy Market Size Trend & Forecast, 2021–2035 (USD Billion) |
FIGURE 5 Global Cell Therapy Market – Year-over-Year Growth Rate, 2022–2035 (%) |
FIGURE 6 Market Share by Therapy Type, 2025 vs 2035 (%) |
FIGURE 7 Market Share by Cell Type, 2025 vs 2035 (%) |
FIGURE 8 Market Share by Application, 2025 (%) |
FIGURE 9 Market Share by End User, 2025 (%) |
FIGURE 10 Regional Market Share Distribution, 2025 (%) |
FIGURE 11 Regional CAGR Comparison, 2026–2035 (%) |
FIGURE 12 North America Country-Level Share Distribution, 2025 (%) |
FIGURE 13 Europe Country-Level Share Distribution, 2025 (%) |
FIGURE 14 Asia-Pacific Country-Level Share Distribution, 2025 (%) |
FIGURE 15 Competitive Landscape – Estimated Revenue Share Bands, 2025 (%) |
FIGURE 16 Competitive Positioning Matrix – Portfolio Breadth vs Manufacturing Scale |
FIGURE 17 Regulatory Milestone Timeline, 2023–2026 |
FIGURE 18 Reimbursement Pathway Coverage Map, 2026

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Therapy Type	Autologous Cell Therapy; Allogeneic Cell Therapy	Autologous Cell Therapy	Allogeneic Cell Therapy
By Cell Type	Immune Cell Therapy; Stem Cell Therapy; Other Cell Types	Immune Cell Therapy	Stem Cell Therapy
By Application	Oncology; Cardiovascular; Neurological Disorders; Musculoskeletal; Dermatology & Wound Care; Other Applications	Oncology	Neurological Disorders
By End User	Hospitals & Clinics; Specialized Cell- & Gene-Therapy Centres; Academic & Research Institutes; Others	Hospitals & Clinics	Specialized Cell- & Gene-Therapy Centres
By Geography	North America; Europe; Asia-Pacific; South America; Middle East & Africa	North America	Asia-Pacific

Market Segmentation Overview

By Therapy Type

Sub-Segment	Key Trend
Autologous Cell Therapy	Label expansion into earlier treatment lines and outpatient administration following REMS removal
Allogeneic Cell Therapy	Breakthrough designations in T-cell malignancies where autologous collection is not feasible

Autologous products carry the installed clinical evidence base and will hold majority revenue through the early 2030s. Allogeneic constructs are competing on logistics rather than efficacy — eliminating collection, bridging therapy, and manufacturing wait entirely.

By Cell Type

Sub-Segment	Key Trend
Immune Cell Therapy	CAR-T, TIL and engineered TCR platforms consolidating around fewer, better-differentiated products
Stem Cell Therapy	First US mesenchymal stromal cell approval reopening a category after prolonged regulatory drought
Other Cell Types	Niche dermal and chondrocyte products serving established musculoskeletal indications

Immune-cell platforms fund the sector's manufacturing infrastructure while stem-cell products supply the growth rate. Neurological and graft-versus-host indications are the categories to watch.

By Application

Sub-Segment	Key Trend
Oncology	Haematologic malignancy moving toward standard-of-care positioning in second line
Cardiovascular	Post-infarction myocardial repair programs in mid-stage development
Neurological Disorders	Late-stage Parkinson's disease pipeline with objective, quantifiable endpoints
Musculoskeletal	Cartilage and tendon repair products with established procedural reimbursement
Dermatology & Wound Care	Chronic wound and burn indications supported by device-adjacent coding
Other Applications	Autoimmune and ophthalmic candidates entering pivotal development

Oncology's dominance is structural, not permanent. Autoimmune and neurological indications address populations large enough to change the sector's manufacturing economics outright.

By End User

Sub-Segment	Key Trend
Hospitals & Clinics	Community site integration accelerating after certification requirements were withdrawn
Specialized Cell- & Gene-Therapy Centres	Payer preference for dedicated infrastructure with documented outcome tracking
Academic & Research Institutes	Point-of-care manufacturing of licensed constructs at fractional pricing
Others	Ambulatory infusion providers entering as toxicity profiles improve

Hospitals retain the majority because they own the apheresis and cryopreservation assets. Dedicated centres grow faster because payers negotiating outcomes-based contracts want consistent, auditable data collection.

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”